Prediction of type 1 diabetes is based on the detection of multiple islet autoantibodies in subjects who are at increased genetic risk. Prediction of the timing of diagnosis is challenging, however. We assessed the utility of HbA 1c levels in predicting the clinical disease in genetically predisposed children with multiple autoantibodies. Cord blood samples from 168,055 newborn infants were screened for class II HLA genotypes in Finland, and 14,876 children with increased genetic risk for type 1 diabetes were invited to participate in regular follow-ups, including screening for diabetes-associated autoantibodies. When two or more autoantibodies were detected, HbA 1c levels were analyzed at each visit. During follow-up, multiple (two or more) autoantibodies developed in 466 children; type 1 diabetes was diagnosed in 201 of these children (43%, progressors), while 265 children remained disease free (nonprogressors) by December 2011. A 10% increase in HbA 1c levels in samples obtained 3-12 months apart predicted the diagnosis of clinical disease (hazard ratio [HR] 5.7 [95% CI 4.1-7.9]) after a median time of 1.1 years (interquartile range [IQR] 0.6-3.1 years) from the observed rise of HbA 1c . If the HbA 1c level was ‡5.9% (41 mmol/mol) in two consecutive samples, the median time to diagnosis was 0.9 years (IQR 0.3-1.5, HR 11.9 [95% CI 8. [8] [9] [10] [11] [12] [13] [14] [15] [16] .0]). In conclusion, HbA 1c is a useful biochemical marker when predicting the time to diagnosis of type 1 diabetes in children with multiple autoantibodies.
The development of type 1 diabetes is characterized by immune-mediated destruction of the pancreatic b-cells, which eventually stop producing insulin. The incidence of type 1 diabetes has been growing worldwide, with the highest incidence rate observed in Finland, where the rate has more than doubled from 1980 to 2005 in children under the age of 15 years (1-3).
More than 50 genes conferring susceptibility to human type 1 diabetes have been identified (4) . The major risk genes are located in the class II HLA region on chromosome 6p21 (5) . Environmental risk factors are believed to interact with susceptibility genes and thereby contribute to the disease process (6, 7) . Currently, type 1 diabetes is predicted by analyzing islet autoantibodies of various specificities in an individual with increased genetic disease susceptibility. The presence of multiple (more than two) autoantibodies provides a cumulative disease risk of 50-60% over the next 5 years in children with risk-conferring HLA class II genotypes (8) , and during the 15-year followup the risk of the development of diabetes is very high (84%) in such children (9) .
Although oral glucose tolerance tests (OGTTs) have been shown to provide relatively good accuracy in the prediction of type 1 diabetes (10,11), more practical markers of glucose metabolism are needed. Glycated hemoglobin A 1c (HbA 1c ) levels could be superior to OGTT results as a predictive measure, since HbA 1c is widely used in clinical practice as an indicator of metabolic control in patients with diabetes, and is generally not affected by short-term variations in food intake and physical activity (12, 13) . The World Health Organization and American Diabetes Association have adapted the recommendation of the International Expert Committee that an HbA 1c value $6.5% (48 mmol/mol) is diagnostic for type 2 diabetes (14) , but no threshold value for the diagnosis of type 1 diabetes has been determined (15) . As a laboratory test, HbA 1c is cost effective and easy to obtain, and it could be useful also in the prediction of type 1 diabetes (16) . Although positivity for multiple islet autoantibodies has been shown to be relatively sensitive in the prediction of type 1 diabetes, there is a lack of a reliable method to predict the onset of type 1 diabetes. In this study, the goal was to monitor HbA 1c levels from the start of positivity for multiple (more than two) autoantibodies and to assess its potential as a predictive marker for type 1 diabetes.
RESEARCH DESIGN AND METHODS

Study Design
The Type 1 Diabetes Prediction and Prevention (DIPP) study is a Finnish population-based study in which children with HLA-conferred susceptibility to type 1 diabetes are observed prospectively from birth (17, 18) . Recruitment of newborn infants for the DIPP study started in November 1994 and still continues in three university hospitals (Oulu, Tampere, and Turku) in Finland. Screening for genetic risk is performed from cord blood. Families with an infant carrying HLA genotypes associated with type 1 diabetes are invited to participate in prospective follow-up at 3-to 12-month intervals until the age of 15 years or until clinical disease is diagnosed. Islet autoantibodies are analyzed at each visit; monitoring of HbA 1c is initiated in children who test positive for at least two different autoantibodies in the same sample, and positivity is confirmed in the subsequent sample. The diagnosis of type 1 diabetes is based on typical symptoms and random high plasma glucose levels, or in asymptomatic patients' diagnostic plasma glucose values in two separate OGTTs, as the World Health Organization recommends (19) . The study population for the current analysis comprises 466 DIPP children who tested positive for multiple autoantibodies in a minimum of two consecutive samples and had at least one HbA 1c sample taken between November 1994 and December 2011. The study has been approved by the ethics committees of the participating university hospital districts. All families participating in the study have provided written informed consent.
Immunological Screening
DIPP participants who seroconverted to positivity for any of the diabetes-associated autoantibodies (islet cell antibodies, insulin autoantibodies, GAD antibodies, and autoantibodies specific for the insulinoma-2-associated antigen) were scheduled for follow-up visits at 3-month intervals. The age at seroconversion was defined as the age at which at least one of the diabetes-associated autoantibodies was detected for the first time. The age at multiple autoantibody positivity was defined as the time point when at least two autoantibodies were detected in the same sample. Autoantibodies were analyzed as described previously (8) . In the Diabetes Autoantibody Standardization (DASP) workshop in 2005, the following sensitivities and specificities were reported: insulin autoantibodies 58% and 96%; GAD antibodies 82% and 96%; and insulinoma-2-associated antigen antibodies 72% and 100%.
Genetic Screening
HLA-conferred susceptibility to type 1 diabetes was analyzed centrally using cord blood, as described previously (20 In the Oulu University Hospital, an immunoassay-based method was applied throughout the study. In the Turku University Hospital, the fast-protein liquid chromatography method was used to measure HbA 1c levels until 5 August 1996 (Pharmacia). Thereafter, highperformance liquid chromatography has been used. The mean HbA 1c level measured in the Oulu University Hospital was 5.57% (SD 0.78); in Tampere University Hospital, it was 5.56% (SD 0.46); and in Turku University Hospital, it was 5.57% (SD 0.51). The covariate adjustment was used in the linear mixed model (LMM) analysis to take into account the possible confounding effect of variable assay levels in the three hospitals.
Statistical Analyses
We established a priori three time-dependent decision rules for HbA 1c . First, children who had undergone at least two HbA 1c measurements within 3-12 months were classified into two groups according to whether they experienced an increase of at least 10% in their HbA 1c values or not (decision rule 1). Second, children who had undergone at least two HbA 1c measurements within 3-12 months and a third HbA 1c measurement during the next 6 months were classified into two groups according to whether they had a 10% increase in HbA 1c values within 3-12 months and any additional increase during the next 6 months or not (decision rule 2). Third, children were divided into two groups according to whether they had two consecutive HbA 1c values $5.9% (41 mmol/mol) or not (decision rule 3). The use of an increase of 10% as a decision rule was based on the data from the three laboratories involved. The interassay coefficient of variation was 3.3% in Oulu University Hospital, 2.0% in Tampere University Hospital, and 2.7% in Turku University Hospital, and the reported uncertainty of measurement values were 10%, 5.8%, and 5.9%, respectively. The calculation of the uncertainty was based on current recommendations (22) . The highest reported percentage of uncertainty was selected for the analysis. The cutoff HbA 1c value of $5.9% (41 mmol/mol) has been suggested in previous studies of the prediction of diabetes (23) (24) (25) . Two sequential measurements were required to minimize the biological and analytical variations. A time window of 3-12 months was used in the analyses according to the DIPP protocol in which follow-up visits occur every 3 months.
Cox regression with these time-dependent covariates was used to evaluate the association between HbA 1c and the risk of diabetes. The entry time to the analysis was the date when at least two islet autoantibodies were positive. All subjects were considered to be unexposed until the time-dependent covariate fulfilled the decision rule, and thereafter the status of the subject was exposed. Consequently, if the subject had only one (decision rules 1 and 3) or two (decision rule 2) HbA 1c measurements, he/she belonged to the unexposed group. Samples taken on the day of diagnosis were excluded from the analyses considering the predictive use of HbA 1c (decision rules), but not from the LMM analysis. The total follow-up time was partitioned into intervals according to the cut points of the decision rule. Univariate Cox regression analysis was performed to identify the risk factors of diabetes, and survival curve estimates were calculated to assess the timing and probability of diabetes after fulfilling a decision rule. Sensitivity and specificity for the three decision rules were also calculated. Multivariate Cox regression with the backward stepwise model was used to identify a set of predictors that are most effective in disease prediction. In the multivariate analysis, the explanatory variable candidates were a 10% increase in HbA 1c values within 3-12 months, a 10% increase in HbA 1c values within 3-12 months and any additional increase during the next 6 months, two consecutive HbA 1c values $5.9% (41 mmol/mol), age at the detection of multiple autoantibodies, type 1 diabetes in a first-degree relative (FDR), HLA risk, and sex.
LMM analysis with a random intercept and first-order autoregressive covariance structure for repeated measurements was used to analyze HbA 1c levels over time between the progressors (children with multiple [two or more] autoantibodies who progressed to overt type 1 diabetes) and nonprogressors (children with multiple autoantibodies in whom clinical disease did not develop during the followup). The random intercepts and repeated measurements were nested within subjects, and subjects were nested within the hospital. The group-by-time interaction was included in the model to test differences between group means at each time point. Sex, age at sampling, age at seroconversion, age at multiple autoantibody positivity, type 1 diabetes in an FDR, and HLA risk were included in the LMM analysis as fixed variables. Differences in proportions were tested using the standardized normal deviate test.
All analyses were performed using IBM SPSS version 20.0.0 for Windows, Stata/IC version 11.2 for Windows, and StatsDirect statistical software version 2.7.9. The figures were drawn using OriginPro version 8.6.0 and Stata/IC version 11.2.
RESULTS
Between November 1994 and December 2011, a total of 168,055 newborn infants were screened for HLAconferred susceptibility to type 1 diabetes. Altogether, 14,876 children with increased genetic risk were enrolled for regular follow-up into the DIPP study. During followup, multiple positive autoantibodies developed in 466 children, and 201 of these children (43%) progressed to type 1 diabetes (progressors), whereas 265 children remained disease free until the end of December 2011 (nonprogressors). In the progressor group, at least two positive autoantibodies were detected in the first positive sample of 136 children (68%), whereas in the nonprogressor group, at least two positive antibodies were detected in the first positive sample of 110 children (42%) (P , 0.001). The baseline characteristics of the children are presented in Table 1 .
Altogether, 4,270 HbA 1c samples were analyzed during the prediabetic period, 1,613 from the progressors and 2,657 from the nonprogressors. An average of 8.0 measurements per child (95% CI 7.0-9.0, range 1-37) were obtained in the group of progressors and 10.0 (95% CI 8.9-11.1, range 1-44) in the group of nonprogressors.
When retrospectively comparing HbA 1c levels between the progressors and nonprogressors, we observed that HbA 1c levels started to be consistently higher in the progressors 2.0 years before the diagnosis (Fig. 1) . More specifically, during the period 1.8-2.0 years before diagnosis, the adjusted mean HbA (Table 2) , and clinical disease developed in half of these children within 1.1 years (interquartile range [IQR] 0.6-3.1 years) (Fig. 2B) according to the univariate Cox regression analysis. When including any additional rise in HbA 1c levels in a third measurement during the subsequent 6 months, the HR was 5.1 (95% CI 3.6-7.2), and overt disease developed in 50% of the children during the next 0.7 years (IQR 0.7-1.5 years) ( Table 2 and Fig. 2C) . If a child was found to have two consecutive HbA 1c values $5.9% (41 mmol/mol), the risk of diabetes was almost 12-fold compared with the remaining children (HR 11.9 [95% CI 8.8-16.0]), and the median time to type 1 diabetes was 0.9 years (IQR 0.3-1.5) ( Table 2 and Fig. 2D ). The most effective set of predictive variables in multivariate Cox regression analysis is shown in Table 3 .
Sensitivities and specificities were calculated for the suggested decision rules. A 10% increase in HbA 1c levels over 3-12 months provided a sensitivity of 57% (95% CI 50-64) and a specificity of 66% (95% CI 60-72). When including an additional rise during the next 6 months, the sensitivity of the test was 22% (95% CI 17-29) and the specificity was 91% (95% CI 87-94). Two consecutive values of HbA 1c $5.9% (41 mmol/mol) presented a sensitivity of 42% (95% CI 35-49) and a specificity of 86% (95% CI 82-90).
When multiple positive autoantibodies were detected, an increase of 10% in HbA 1c values appeared after a mean time of 2.5 years (SD 2.0 years). For an additional rise, the 
DISCUSSION
The prediction of type 1 diabetes has so far been based mainly on the presence of islet autoantibodies in subjects who are at increased genetic risk (8, 26, 27) . Young age at seroconversion also has a clear impact on the risk of progression to clinical disease (17) . In addition to autoantibodies, consecutive OGTT results have been of interest in the prediction of type 1 diabetes, giving at best almost 90% accuracy during a 2-year follow-up among the relatives of patients affected by type 1 diabetes (10,11,28-31) . When evaluating the potential of HbA 1c level as an additional marker in the prediction of type 1 diabetes, we looked for new and practical ways to predict the timing of the diagnosis. The following three new criteria were established: a 10% rise in HbA 1c values taken 3-12 months apart, an additional rise during the subsequent 6 months, and two consecutive values of $5.9% (41 mmol/mol) that could be used to predict the clinical disease in a child with multiple autoantibodies. These results are important since families with a child positive for multiple islet autoantibodies are concerned about the time remaining until the development of clinical disease. They are well aware of the high disease risk and need expert counseling. Stable HbA 1c values in consecutive measurements suggest that the child is not going to present with overt diabetes in the near future. In contrast, an increase in HbA 1c level gives a warning of incipient disease, which may help in early diagnosis and thereby reduce the risk of acute complications, such as diabetic ketoacidosis (32) .
Age at multiple (two or more) autoantibody positivity, the time from seroconversion to multiple autoantibodies, the presence of affected FDRs, and a high-risk HLA class II genotype have previously been identified as risk factors for type 1 diabetes (8, 16, 17, 33) . In our analyses, age at multiple autoantibody positivity was a significant predictive factor in both univariate and multivariate analyses. Children with an affected FDR had more than a twofold disease risk, demonstrating that genetic factors also have an important effect on the progression from b-cell autoimmunity to clinical disease. The HLA class II genotype appeared to play a role in disease progression, although with a lower HR than the HbA 1c variables.
Our prediabetic cohort of 201 Finnish children with multiple autoantibodies represents the largest series of young children who have participated in a long-term intensive follow-up from birth to diagnosis of type 1 diabetes. Only one study (16) on the evolution of HbA 1c levels during prediabetes has been published earlier. Although that study included a relatively small number of 28 islet autoantibody-positive children who progressed to clinical diabetes, the results were similar to our study's, showing that HbA 1c levels start to increase within the normal reference range and that the rise is steepest during the last 6 months before diagnosis. The strength of our study is the fact that with a considerably larger sample size and higher number of HbA 1c measurements per child we were able to get more accurate and reliable estimates when analyzing the predictive characteristics of HbA 1c . Our study population came from three clinical centers that used different methods to analyze HbA 1c , which might have produced slightly different absolute values. This was taken into account using covariate adjustment in the analyses. Furthermore, we used a relative increase in HbA 1c values rather than absolute values in our predictive model to make the results of our study more generalizable. Currently, there are no exact threshold values for a significant change in HbA 1c levels. Our decision rules were based on the available literature and variances reported by the university hospital laboratories involved, and they are described in more detail in the RESEARCH DESIGN AND METHODS section.
The suggested decision rules of a 10% rise in HbA 1c level during 3-12 months and two consecutive HbA 1c values $5.9% (41 mmol/mol) both provide high HRs with relatively short median time to diagnosis of type 1 diabetes (1.1 and 0.9 years, respectively). However, a 10% rise provides superior sensitivity (57% vs. 42%), whereas two consecutive results of $5.9% (41 mmol/mol) has a higher specificity (86% vs. 66%). Since children with multiple (two or more) autoantibodies have a high risk of the development of type 1 diabetes over a variable period of time, it is probably more practical from the clinical point of view to use two consecutive HbA 1c results $5.9% in the prediction of the timing of diagnosis. It is still noteworthy that a relative increase of 10% in HbA 1c level is more independent from methodological differences and reference values, therefore remaining important alongside the absolute values.
Our retrospective analysis showed that HbA 1c values start to increase~2 years before the diagnosis, reflecting the gradual deterioration in endogenous insulin secretion and increasing fluctuation in plasma glucose levels. There were some differences in the demographic characteristics between the nonprogressors and the progressors, however. The nonprogressors were older both at initial seroconversion and when multiple autoantibodies developed.
The mean age of the nonprogressors was 10.9 years at the end of follow-up, whereas the age of the progressors at diagnosis was 6.3 years. The nonprogressors had affected family members less often. On the other hand, our data show that the mean HbA 1c level remained very stable in the children in the nonprogressor group during the follow-up, varying from 5.3% (34 mmol/mol) to 5.6% (38 mmol/mol), and therefore the differences in age and followup time are probably not interfering with this analysis.
Our results provide important data on the natural evolution of HbA 1c levels during the prediabetic period in young children, which can be used in future prevention trials. In secondary prevention trials aimed at slowing down or reversing the progression of b-cell dysfunction in subjects with islet autoantibodies, there is a clear need for markers that can be used to monitor the disease process. HbA 1c level is an indirect measure of glucose control and cannot be used as a direct estimate of b-cell function. It is noteworthy that the time interval between the HbA 1c measurements used to calculate the presence or absence of a 10% increase varied between 3 and 12 months, and may represent a potential confounder, given that a 10% increase occurring during a 3-month interval might have a different weight in terms of prediction compared with a similar increase in samples derived from a 12-month interval. As HbA 1c level represents a variation in plasma glucose levels during the lifetime of erythrocytes (120 days), with the weight on the preceding 6-8 weeks, it seems unnecessary to measure HbA 1c levels more often than every 3 months. Since the three laboratories involved reported rather high uncertainty of measurements varying from 5.8% to 10% and the methodology changed over the study period, one has to consider the possibility that some changes in HbA 1c levels are due to variations in methodology. However, this possible source of error affects the progressor and nonprogressor groups equally. The HbA 1c values suggested on the basis of the current analyses for the prediction of clinical type 1 diabetes are from a single study, and validation of the results is needed in additional populations.
In conclusion, we have shown that HbA 1c level is a useful biochemical marker for the estimation of the time to the diagnosis of type 1 diabetes in genetically susceptible children with multiple islet autoantibodies. 
